BioShin

About

BioShin is a clinical stage biopharmaceutical company.

Shanghai,Shanghai,China
1 - 10

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $60M
Industries: Biotechnology,Health Care,Life Science,Pharmaceutical
Founded date: Jan 1, 2013
Number Of Employee: 1 - 10
Operating Status: Active
Legal Name: BioShin Ltd.

BioShin is a wholly owned subsidiary of Biohaven Pharmaceuticals, a public biotech company. BioShin is a clinical stage biopharmaceutical company focused on developing medicines. It has proven leadership from global industry and academic settings and a portfolio of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

1

$60M

BioShin has raised a total of $60M in funding over 2 rounds. Their latest funding was raised on Sep 28, 2020 from a Series A round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Sep 28, 2020	Series A	$60M	5	OrbiMed	—	Detail

Investors

Number of Lead Investors

Number of Investors

1

5

BioShin is funded by 5 investors. OrbiMed and Cormorant Asset Management are the most recent investors.

Investor Name	Lead Investor	Funding Round
OrbiMed	Yes	Series A
Cormorant Asset Management	—	Series A
HBM Healthcare Investments AG	—	Series A
Surveyor Capital	—	Series A
Suvretta Capital Management	—	Series A